小児の不眠症
Rayan Kteish1, Mathew Ednick1, Catherine Kier1
1Stony Brook Children's Hospital, Renaissance School of Medicine, Stony Brook, New York.
Pediatrics in review
|December 31, 2025
まとめ
小児の不眠症は、子供の睡眠困難であり、特に自閉スペクトラム症(ASD)または注意欠陥・多動性障害(ADHD)を持つ子供によく見られます。認知行動療法(CBT-I)が最も効果的な治療法です。
科学分野:
- 小児科
- 睡眠医学
- 児童心理学
背景:
- 小児の不眠症は、睡眠の開始または維持の困難を特徴とし、子供の幸福に著しい影響を与えます。
- 自閉スペクトラム症(ASD)および注意欠陥・多動性障害(ADHD)を持つ子供では、不眠症の有病率が高くなります。
- 一般的なサブタイプには、行動性不眠症および心身症性不眠症が含まれます。
主な方法:
- 小児の不眠症のサブタイプ、有病率、および関連状態の臨床的レビュー。
- 小児科医のための現在の診断上の課題と管理アプローチの評価。
- 認知行動療法(CBT-I)およびメラトニンのような薬理学的選択肢のエビデンスの評価。
結論:
- 小児科医は、併存疾患を考慮して、不眠症の診断と管理に注意を払う必要があります。
- 慢性的な不眠症とその精神的健康への悪影響を防ぐためには、早期介入が重要です。
- CBT-Iは第一選択治療であり、メラトニンは特定の集団における潜在的な補助療法です。
関連する概念動画
Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Management of Insomnia
498
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
498
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Insomnia
378
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
378
Sedatives and Hypnotics Drugs: Miscellaneous Agents
475
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
475


